2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
"2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A selective D1 dopamine receptor agonist used primarily as a research tool.
| Descriptor ID |
D015647
|
| MeSH Number(s) |
D03.633.100.079.800
|
| Concept/Terms |
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine- 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
- 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-1-phenyl-
SK&F-38393- SK&F-38393
- SK&F 38393
- SK&F38393
- SKF38393
- SKF-38393
- SKF 38393
- R-SK&F 38393
- RSK&F 38393
- SKF 38393-A
- SKF 38393 A
- SKF 38393A
|
Below are MeSH descriptors whose meaning is more general than "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine".
Below are MeSH descriptors whose meaning is more specific than "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine".
This graph shows the total number of publications written about "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine" by people in this website by year, and whether "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 2 | 2 | 4 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine" by people in Profiles.
-
Tempol reduces oxidative stress and restores renal dopamine D1-like receptor- G protein coupling and function in hyperglycemic rats. Am J Physiol Renal Physiol. 2006 Jul; 291(1):F58-66.
-
Tempol reduces oxidative stress, improves insulin sensitivity, decreases renal dopamine D1 receptor hyperphosphorylation, and restores D1 receptor-G-protein coupling and function in obese Zucker rats. Diabetes. 2005 Jul; 54(7):2219-26.
-
Rosiglitazone restores G-protein coupling, recruitment, and function of renal dopamine D1A receptor in obese Zucker rats. Hypertension. 2004 Feb; 43(2):376-82.
-
Reduced renal dopamine D1 receptor function in streptozotocin-induced diabetic rats. Am J Physiol Renal Physiol. 2004 Mar; 286(3):F451-7.
-
Diminished natriuretic response to dopamine D1 receptor agonist, SKF-38393 in obese Zucker rats. Clin Exp Hypertens. 2003 Nov; 25(8):509-15.
-
Overexpression of PKC-betaI and -delta contributes to higher PKC activity in the proximal tubules of old Fischer 344 rats. Am J Physiol Renal Physiol. 2003 Dec; 285(6):F1100-7.
-
Dopamine-mediated inhibition of renal Na,K-ATPase is reduced by insulin. Hypertension. 2003 Jun; 41(6):1353-8.
-
Higher basal serine phosphorylation of D1A receptors in proximal tubules of old Fischer 344 rats. Am J Physiol Renal Physiol. 2002 Aug; 283(2):F350-5.
-
Hyperphosphorylation of Na-pump contributes to defective renal dopamine response in old rats. J Am Soc Nephrol. 2001 Feb; 12(2):226-232.